摘要
目的观察干扰素联合苦参素用药后 PreS1与 HBeAg 和 HBV-DNA 的相关性,探讨 PreS1在乙肝抗病毒治疗过程中的临床意义及实验室诊断价值。方法收集乙肝患者和乙肝抗病毒治疗者血清100份,检测 PreS1、HBV-M 和 HBV-DNA 等,分析 PreS1在抗病毒治疗前后与 HBeAg 和 HBV-DNA 的相关性。结果对照组 HBsAg 和 HBV-DNA 阳性50人,其中 HBeAg 阳性30人中29人 PreS1阳性,HBeAg 阴性20人中17人 PreS1阳性。治疗组50人,2个疗程的抗病毒治疗后抽血检查相关指标,显效组5人,治疗后血清学应答、病毒学应答均转阴。有效组19人治疗后血清学应答不同,病毒学应答(HBV-DNA)均下降2～3个数量级。无效组26人,治疗后血清学应答无变化,病毒学应答(HBV-DNA)有30%的下降1～2个数量级。结论PreS1在 HBeAg 发生变异时可以补充表达 HBV 病毒的活动性.为临床判断 HBV 病毒存在、复制及抗病毒疗效观察提供实验室依据。
Objective To observe the clinical significance and laboratory diagnostic values of Pre-S1 antigens （Pre-S1） and its relativity to HBeAg and HBV-DNA after using interferon in association with kurarinone. Methods The content of Pre-S1 and HBV-M was detected by ELISA and the levels of HBV-DNA were detected by florescence quantitative PCR（FQ-PCR） in 100 serum samples of patients with HBV infection and patients after an antiviral treatment. Results Matched control in 50 serum of HBsAg-posidve and detectable HBV-DNA cases, both 29 samples in 30 HBeAg-positive cases and 17 samples in 20 HBeAg-negative cases Pre-Sls were positive. Treatment set 50 serum of patients after taking two courses of an antiviral treatment for HBV infection,drawing blood to observe related markers,5 cases Of effect set were turned into negative for serologic markers and virologic markers. 19 cases of valid set,serologic markers were various and the HBV-DNA copies descended 2-3 orders of magnitude. 26 cases of invalid set ,serologic markers were not various, and 30 % samples of the HBV-DNA copies descended 1- 2 orders of magnitude. Conclusion It was supplementary for Pre-S1 to indicate HBV expression when the HBeAg varied. It also provided detectable laboratory markers in HBV infectivity,replication and therapeutic efficiency evaluation.
出处
《中国基层医药》
CAS
2007年第7期1095-1096,共2页
Chinese Journal of Primary Medicine and Pharmacy
